医学
多丽丝(腹足类)
工作队
任务(项目管理)
公共行政
政治学
病毒学
经济
管理
作者
Ronald van Vollenhoven,George Βertsias,Andrea Doria,David Isenberg,Eric F. Morand,Michelle Petri,Bernardo A. Pons‐Estel,Anisur Rahman,Manuel F. Ugarte‐Gil,Alexandre E. Voskuyl,Laurent Arnaud,Ian N Bruce,Ricard Cervera,N. Costedoat‐Chalumeau,Caroline Gordon,Frédéric Houssiau,Marta Mosca,Matthias Schneider,Michael M. Ward,Graciela S. Alarcón
标识
DOI:10.1136/lupus-2021-000538
摘要
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI